Health economic analysis of fluoropyrimidine-based therapies of colorectal cancer from the perspective of statutory sickness funds

Zeitschrift fur Gastroenterologie

Volumn 43, Issue 2, 2005, Pages 155-161

  Grothey, A ^a,e   Kleeberg, U R ^b   Stauch, M ^c   Hieke, Klaus ^d,e  

^a MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^b HOPA   (Germany)

^c NEOS Health ^*

^d MAYO CLINIC   (United States)

^e NEOS Health   (Switzerland)

Author keywords

Colorectal cancer; Oral administration; Treatment costs; Treatment setting

Indexed keywords

CAPECITABINE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID;

ALOPECIA; AMBULATORY CARE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL PROTOCOL; COLORECTAL CANCER; COST CONTROL; DIARRHEA; DRUG COST; FINANCIAL MANAGEMENT; GERMANY; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH INSURANCE; HOSPITAL CARE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; NAUSEA; NEUTROPENIA; SEPSIS; STOMATITIS; UNIVERSITY HOSPITAL;

ADMINISTRATION, ORAL; AMBULATORY CARE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CATHETERS, INDWELLING; COLORECTAL NEOPLASMS; COST SAVINGS; DEOXYCYTIDINE; DRUG COSTS; FEE SCHEDULES; FLUOROURACIL; GERMANY; HEALTH CARE COSTS; HOSPITALS, MUNICIPAL; HOSPITALS, UNIVERSITY; HUMANS; NATIONAL HEALTH PROGRAMS; PATIENT ADMISSION;

EID: 14744300698     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-813708     Document Type: Article

References (19)

1. Robert-Koch-Institut, Berlin, Germany, http://www.rki.de/GBE/KREBS/KREBS. HTM
2. Jonker DJ, Maroun JA, Kocha W. Survival benefit of chemotherapy in metastatic colorectal cancer: a meta-analysis of randomized controlled trials. Br J Cancer 2000; 82: 1789-1794
3. Grothey A, Schmoll HJ. New chemotherapy approaches in colorectal cancer. Curr Opin Oncol 2001; 13: 275-286
4. Grothey A et al. Defizite in der Behandlung von Patienten mit kolorektalem Karzinom in Deutschland. Med Klinik 2002; 97: 270-277
5. Twelves C. Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials. Eur J Cancer 2002; 38 (Suppl 2): 15-20
6. Cassidy J, Twelves C, Van Cutsem E et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002; 13: 566-575
7. Herold M, Hieke K. Costs of drug delivery for CHOP, COP/CVP, and fludarabine: an international assessment. Value Health 2003; 6: 167-174
8. Herold M, Sacchi S, Hieke K. The cost of treating relapsed indolent non-Hodgkin's lymphoma in an international setting: retrospective analysis of resource use. Haematologica 2002; 87: 719-729
9. Twelves C, Boyer M, Findlay M et al. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer 2001; 37: 597-604
10. A review of the evidence for the clinical and cost effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer. The University of Sheffield on behalf of the National Institute for Clinical Excellence (NICE), 2002 (accessed at http://www.nice.org.uk/Docref.asp? d = 52 481)
11. Liu G, Franssen E, Fitch MI et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15: 110-115
12. Borras JM, Sanchez-Hernandez A, Navarro M et al. Compliance, satisfaction, and quality of life of patients with colorectal cancer receiving home chemotherapy or outpatient treatment: a randomised controlled trial. BMJ 2001; 322: 826
13. Oncology Information Service. Therapiemonitor kolorektale Karzinome. Data on file 2001
14. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30; Epub 2003 Dec 09
15. Grothey A, Jordan K, Kellner O et al. Randomized phase II trial of capecitabine plus irinotecan (CapIri) vs capecitabine plus oxaliplatin (CapOx) as first-line therapy of advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2003; 22: 255; abstract 1022
16. Kerr D, Ten Bokkel Huinink W, Ferry D et al. A phase I/II study of CPT-11 in combination with capecitabine as first line chemotherapy for metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2002; 21: 161 a; abstract 643
17. Sastre J, Butts C, Cassidy J et al. Capecitabine-oxaliplatin combination (XELOX), effective 1st line therapy for patients (pts) with metastatic colorectal cancer (MCRC): Survival update of an international phase II trial. Ann Oncol 2002; 13 (Suppl. 5): 80; abstract 288P
18. Chu E, Diaz-Rubio E, Marshall J et al. Economic analysis of potential medical cost savings of XELOX (capecitabine and oxaliplatin combination) in metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2003; 22: 269; abstract 1080
19. Glocker S, Roeder N. Onkologie im G-DRG-System 2004. Onkologe 2003; 9: 1375-1380